August 14, 2023Open Access

US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events

Key Points

Key points are not available for this paper at this time.

Abstract

Semaglutide treatment in eligible US adults may substantially reduce obesity prevalence and CVD events, which may dramatically impact associated healthcare costs.

Bookmark

View Full Paper

Cite This Study

Wong et al. (Mon,) studied this question.

synapsesocial.com/papers/69d72dbad2e0540b79f507ae https://doi.org/https://doi.org/10.1007/s10557-023-07488-3

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes2016 · 7,354 citations
2Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)2021 · 11 citations
3Validity of Self-reported Diagnoses Leading to Hospitalization: A Comparison of Self-reports with Hospital Records in a Prospective Study of American Adults1998 · 356 citations
4General Cardiovascular Risk Profile for Use in Primary Care2008 · 7,468 citations
5Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design2020 · 239 citations

Bookmark

View Full Paper